Patents by Inventor Howard R. Levin

Howard R. Levin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8684998
    Abstract: Methods and apparatus are provided for thermally-induced renal neuromodulation. Thermally-induced renal neuromodulation may be achieved via direct and/or via indirect application of thermal energy to heat or cool neural fibers that contribute to renal function, or of vascular structures that feed or perfuse the neural fibers. In some embodiments, parameters of the neural fibers, of non-target tissue, or of the thermal energy delivery element, may be monitored via one or more sensors for controlling the thermally-induced neuromodulation. In some embodiments, protective elements may be provided to reduce a degree of thermal damage induced in the non-target tissues.
    Type: Grant
    Filed: March 9, 2012
    Date of Patent: April 1, 2014
    Assignee: Medtronic Ardian Luxembourg S.a.r.l.
    Inventors: Denise Demarais, Nicolas Zadno, Benjamin J. Clark, Erik Thai, Howard R. Levin, Mark Gelfand
  • Publication number: 20140088561
    Abstract: A method and apparatus for treatment of heart failure, hypertension and renal failure by stimulating the renal nerve. The goal of therapy is to reduce sympathetic activity of the renal nerve. Therapy is accomplished by at least partially blocking the nerve with drug infusion or electrostimulation. Apparatus can be permanently implanted or catheter based.
    Type: Application
    Filed: November 21, 2013
    Publication date: March 27, 2014
    Applicant: Medtronic Ardian Luxembourg S.a.r.l.
    Inventors: Howard R. Levin, Mark Gelfand
  • Publication number: 20140081259
    Abstract: Methods and apparatus are provided for renal neuromodulation using a pulsed electric field to effectuate electroporation or electrofusion. It is expected that renal neuromodulation (e.g., denervation) may, among other things, reduce expansion of an acute myocardial infarction, reduce or prevent the onset of morphological changes that are affiliated with congestive heart failure, and/or be efficacious in the treatment of end stage renal disease. Embodiments of the present invention are configured for percutaneous intravascular delivery of pulsed electric fields to achieve such neuromodulation.
    Type: Application
    Filed: October 17, 2013
    Publication date: March 20, 2014
    Applicant: Medtronic Ardian Luxembourg S.a.r.l.
    Inventors: Mark E. Deem, Hanson Gifford, III, Denise Zarins, Douglas Sutton, Erik Thai, Mark Gelfand, Howard R. Levin
  • Publication number: 20140058377
    Abstract: Methods and apparatus are provided for renal neuromodulation using a pulsed electric field to effectuate electroporation or electrofusion. It is expected that renal neuromodulation (e.g., denervation) may, among other things, reduce expansion of an acute myocardial infarction, reduce or prevent the onset of morphological changes that are affiliated with congestive heart failure, and/or be efficacious in the treatment of end stage renal disease. Embodiments of the present invention are configured for percutaneous intravascular delivery of pulsed electric fields to achieve such neuromodulation.
    Type: Application
    Filed: October 17, 2013
    Publication date: February 27, 2014
    Applicant: Medtronic Ardian Luxembourg S.a.r.l.
    Inventors: Mark E. Deem, Hanson Gifford, III, Denise Zarins, Douglas Sutton, Erik Thai, Mark Gelfand, Howard R. Levin
  • Publication number: 20140018880
    Abstract: Methods and apparatus are provided for monopolar neuromodulation, e.g., via a pulsed electric field. Such monopolar neuromodulation may effectuate irreversible electroporation or electrofusion, necrosis and/or inducement of apoptosis, alteration of gene expression, action potential attenuation or blockade, changes in cytokine up-regulation and other conditions in target neural fibers. In some embodiments, monopolar neuromodulation is applied to neural fibers that contribute to renal function. In some embodiments, such monopolar neuromodulation is performed bilaterally.
    Type: Application
    Filed: August 2, 2013
    Publication date: January 16, 2014
    Applicant: Medtronic Ardian Luxembourg S.a.r.l.
    Inventors: Denise Zarins, Hanson Gifford, III, Mark Deem, Howard R. Levin, Mark Gelfand, Nicolas Zadno
  • Publication number: 20140018723
    Abstract: Methods and apparatus are provided for renal neuromodulation using a pulsed electric field to effectuate electroporation or electrofusion. It is expected that renal neuromodulation (e.g., denervation) may, among other things, reduce expansion of an acute myocardial infarction, reduce or prevent the onset of morphological changes that are affiliated with congestive heart failure, and/or be efficacious in the treatment of end stage renal disease. Embodiments of the present invention are configured for percutaneous intravascular delivery of pulsed electric fields to achieve such neuromodulation.
    Type: Application
    Filed: June 28, 2013
    Publication date: January 16, 2014
    Applicant: Medtronic Ardian Luxembourg S.a.r.l.
    Inventors: Mark E. Deem, Hanson Gifford, III, Denise Zarins, Douglas Sutton, Erik Thai, Mark Gelfand, Howard R. Levin
  • Publication number: 20140018879
    Abstract: Methods and apparatus are provided for renal neuromodulation using a pulsed electric field to effectuate electroporation or electrofusion. It is expected that renal neuromodulation (e.g., denervation) may, among other things, reduce expansion of an acute myocardial infarction, reduce or prevent the onset of morphological changes that are affiliated with congestive heart failure, and/or be efficacious in the treatment of end stage renal disease. Embodiments of the present invention are configured for extravascular delivery of pulsed electric fields to achieve such neuromodulation.
    Type: Application
    Filed: July 15, 2013
    Publication date: January 16, 2014
    Applicant: Medtronic Ardian Luxembourg S.a.r.l.
    Inventors: Mark Deem, Denise Demarais, Douglas Sutton, Hanson Gifford, III, Howard R. Levin, Mark Gelfand, Benjamin J. Clark
  • Patent number: 8626300
    Abstract: Methods and apparatus are provided for thermally-induced renal neuromodulation. Thermally-induced renal neuromodulation may be achieved via direct and/or via indirect application of thermal energy to heat or cool neural fibers that contribute to renal function, or of vascular structures that feed or perfuse the neural fibers. In some embodiments, parameters of the neural fibers, of non-target tissue, or of the thermal energy delivery element, may be monitored via one or more sensors for controlling the thermally-induced neuromodulation. In some embodiments, protective elements may be provided to reduce a degree of thermal damage induced in the non-target tissues. In some embodiments, thermally-induced renal neuromodulation is achieved via delivery of a pulsed thermal therapy.
    Type: Grant
    Filed: March 11, 2011
    Date of Patent: January 7, 2014
    Assignee: Medtronic Ardian Luxembourg S.a.r.l.
    Inventors: Denise Demarais, Andrew Wu, Hanson Gifford, III, Mark Deem, Mark Gelfand, Howard R. Levin
  • Patent number: 8603021
    Abstract: An ultrafiltration filter for an extracorporeal blood circuit having an input for blood withdrawn from a human patient and a blood output for filtered blood to be infused into the patient including: a filter body having a length of at least 20 centimeters (cm) and an interior diameter of no greater than 1.5 cm; an input at a first end of the body to receive the withdrawn blood; an output at a second end of the body to discharge the filtered blood; a filter membrane in the body defining a blood passage through the body, wherein the membrane has an active filter membrane surface area of no greater than 0.2 meters squared (m2) and the filter membrane blocks passage of blood molecules having a molecular weight cut of greater than 60,000 Daltons and a volume of the blood passage in the filter being less than two percent of a cardiac output of the patient, and an ultrafiltrate output to the body and open to a side of the filter surface area opposite to the blood passage.
    Type: Grant
    Filed: May 2, 2011
    Date of Patent: December 10, 2013
    Assignee: Gambro UF Solutions, Inc.
    Inventors: Howard R. Levin, Mark Gelfand, John O'Mahony, Hans-Dietrich Polaschegg
  • Patent number: 8548600
    Abstract: Methods and apparatus are provided for renal neuromodulation using a pulsed electric field to effectuate electroporation or electrofusion. It is expected that renal neuromodulation (e.g., denervation) may, among other things, reduce expansion of an acute myocardial infarction, reduce or prevent the onset of morphological changes that are affiliated with congestive heart failure, and/or be efficacious in the treatment of end stage renal disease. Embodiments of the present invention are configured for percutaneous intravascular delivery of pulsed electric fields to achieve such neuromodulation.
    Type: Grant
    Filed: September 14, 2012
    Date of Patent: October 1, 2013
    Assignee: Medtronic Ardian Luxembourg S.a.r.l.
    Inventors: Mark Deem, Hanson Gifford, III, Denise Demarais, Douglas Sutton, Erik Thai, Mark Gelfand, Howard R. Levin
  • Publication number: 20130253471
    Abstract: Methods and apparatus are provided for treating contrast nephropathy, e.g., via a pulsed electric field, via a stimulation electric field, via localized drug delivery, via high frequency ultrasound, via thermal techniques, etc. Such neuromodulation may effectuate irreversible electroporation of electrofusion, necrosis and/or inducement of apoptosis, alteration of gene expression, action potential attenuation or blockade, changes in cytokine up-regulation and other conditions in target neural fibers. In some embodiments, neuromodulation is applied to neural fibers that contribute to renal function. In some embodiments, such neuromodulation is performed in a bilateral fashion. Bilateral renal neuromodulation may provide enhanced therapeutic effect in some patients as compared to renal neuromodulation performed unilaterally, i.e., as compared to renal neuromodulation performed on neural tissue innervating a single kidney.
    Type: Application
    Filed: May 21, 2013
    Publication date: September 26, 2013
    Applicant: Medtronic Ardian Luxembourg S.a.r.I.
    Inventors: Denise Demarais, Hanson Gifford, III, Mark Deem, Douglas Sutton, Howard R. Levin, Mark Gelfand
  • Publication number: 20130253603
    Abstract: A method and apparatus for treatment of heart failure, hypertension and renal failure by stimulating the renal nerve. The goal of therapy is to reduce sympathetic activity of the renal nerve. Therapy is accomplished by at least partially blocking the nerve with drug infusion or electrostimulation. Apparatus can be permanently implanted or catheter based.
    Type: Application
    Filed: April 11, 2013
    Publication date: September 26, 2013
    Applicant: Medtronic Ardian Luxembourg S.a.r.l.
    Inventors: Howard R. Levin, Mark Gelfand
  • Patent number: 8506511
    Abstract: An extracorporeal blood circuit including: a withdrawal conduit connectable to a coronary withdrawal catheter; a withdrawal pump connectable to the withdrawal conduit, wherein a pumping rate of the withdrawal pump determines a blood withdrawal rate from the coronary withdrawal catheter; a filter having an input connected to the withdrawal conduit and a blood output connected to an infusion conduit and a filtrate output connected to a filtrate conduit; a filtrate measurement device to determine an amount of filtrate removed from the blood in the filter; a fluid supplementation conduit providing a blood replacement fluid to at least one of the withdrawal conduit, filter and infusion conduit; a supplementation pump connectable to the fluid supplementation conduit, wherein a pumping rate of the supplementation pump determines a rate at which the blood replacement fluid flows into the blood flowing through the blood circuit, and a controller regulating the pumping rate of the supplementation pump such that the rat
    Type: Grant
    Filed: January 5, 2007
    Date of Patent: August 13, 2013
    Assignee: Gambro UF Solutions, Inc.
    Inventors: Steven J. Bernard, John J. O'Mahony, Andrew V. Halpert, Mark Gelfand, Howard R. Levin
  • Publication number: 20130165989
    Abstract: An implantable medical device for treating breathing disorders such as central sleep apnea wherein stimulation is provided to the phrenic never through a transvenous lead system with the stimulation beginning after inspiration to extend the duration of a breath and to hold the diaphragm in a contracted condition.
    Type: Application
    Filed: June 29, 2012
    Publication date: June 27, 2013
    Inventors: Mark Gelfand, Howard R. Levin, Andrew Halpert
  • Patent number: 8444623
    Abstract: A patient hydration method includes administering hydration fluid to a patient, and a hydration fluid measurement device responsible to a source of hydration fluid, a patient urine output measurement device. A controller is responsive to the hydration fluid measurement device and the patient urine output measurement device. The controller operates the infusion device, in response to the patient urine output measurement device and the hydration fluid measurement device, to hydrate the patient based on the patient's urine output.
    Type: Grant
    Filed: June 6, 2011
    Date of Patent: May 21, 2013
    Assignee: PLC Medical Systems, Inc.
    Inventors: Mark Gelfand, Howard R. Levin
  • Publication number: 20130116685
    Abstract: Methods and apparatus are provided for renal neuromodulation using a pulsed electric field to effectuate electroporation or electrofusion. It is expected that renal neuromodulation (e.g., denervation) may, among other things, reduce expansion of an acute myocardial infarction, reduce or prevent the onset of morphological changes that are affiliated with congestive heart failure, and/or be efficacious in the treatment of end stage renal disease. Embodiments of the present invention are configured for percutaneous intravascular delivery of pulsed electric fields to achieve such neuromodulation.
    Type: Application
    Filed: September 14, 2012
    Publication date: May 9, 2013
    Applicant: Ardian, Inc.
    Inventors: Mark Deem, Hanson Gifford, III, Denise Demarais, Douglas Sutton, Erik Thai, Mark Gelfand, Howard R. Levin
  • Publication number: 20130012844
    Abstract: Methods and apparatus are provided for thermally-induced renal neuromodulation. Thermally-induced renal neuromodulation may be achieved via direct and/or via indirect application of thermal energy to heat or cool neural fibers that contribute to renal function, or of vascular structures that feed or perfuse the neural fibers. In some embodiments, parameters of the neural fibers, of non-target tissue, or of the thermal energy delivery element, may be monitored via one or more sensors for controlling the thermally-induced neuromodulation. In some embodiments, protective elements may be provided to reduce a degree of thermal damage induced in the non-target tissues.
    Type: Application
    Filed: September 14, 2012
    Publication date: January 10, 2013
    Applicant: Ardian, Inc.
    Inventors: Denise Demarais, Nicolas Zadno, Benjamin J. Clark, Erik Thai, Howard R. Levin, Mark Gelfand
  • Publication number: 20130012866
    Abstract: Methods and apparatus are provided for renal neuromodulation using a pulsed electric field to effectuate electroporation or electrofusion. It is expected that renal neuromodulation (e.g., denervation) may, among other things, reduce expansion of an acute myocardial infarction, reduce or prevent the onset of morphological changes that are affiliated with congestive heart failure, and/or be efficacious in the treatment of end stage renal disease. Embodiments of the present invention are configured for percutaneous intravascular delivery of pulsed electric fields to achieve such neuromodulation.
    Type: Application
    Filed: September 14, 2012
    Publication date: January 10, 2013
    Applicant: Ardian, Inc.
    Inventors: Mark Deem, Hanson Gifford, III, Denise Demarais, Douglas Sutton, Erik Thai, Mark Gelfand, Howard R. Levin
  • Publication number: 20130013024
    Abstract: A method and apparatus for treatment of heart failure, hypertension and renal failure by stimulating the renal nerve. The goal of therapy is to reduce sympathetic activity of the renal nerve. Therapy is accomplished by at least partially blocking the nerve with drug infusion or electrostimulation. Apparatus can be permanently implanted or catheter based.
    Type: Application
    Filed: September 14, 2012
    Publication date: January 10, 2013
    Applicant: Ardian, Inc.
    Inventors: Howard R. Levin, Mark Gelfand
  • Patent number: 8244359
    Abstract: An implantable medical device for treating breathing disorders such as central sleep apnea wherein stimulation is provided to the phrenic never through a transvenous lead system with the stimulation beginning after inspiration to extend the duration of a breath and to hold the diaphragm in a contracted condition.
    Type: Grant
    Filed: November 17, 2006
    Date of Patent: August 14, 2012
    Assignee: Respicardia, Inc.
    Inventors: Mark Gelfand, Howard R. Levin, Andrew Halpert